Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9046764 | 0.91 | MEN1 (0.64) | MEN1KMT2AACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL7887346 | 0.86 | NPC1 (0.53) | MEN1KMT2ABACE1SIGMAR1FUCA1 | |
| Hydrochloric Acid SCHEMBL7888835 | 0.86 | MEN1 (0.54) | MEN1KMT2AACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL7886654 | 0.85 | MEN1 (0.63) | MEN1KMT2AACHEBACE1BCHE | |
| SCHEMBL6352566 | 0.84 | MEN1 (0.86) | MEN1KMT2AACHEBACE1BCHE | |
| SCHEMBL12975924 | 0.83 | FUCA1 (0.53) | MEN1KMT2AACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL2883130 | 0.82 | SIGMAR1 (0.54) | ACHEPOLBSIGMAR1FUCA1SLC18A3 | |
| SCHEMBL6042765 | 0.80 | FUCA1 (0.53) | CHRM4SIGMAR1FUCA1SLC18A3 | |
| SCHEMBL6042122 | 0.80 | MEN1 (0.63) | MEN1KMT2AACHEBACE1SIGMAR1 | |
| SCHEMBL7890766 | 0.80 | SIGMAR1 (0.49) | ACHESIGMAR1FUCA1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1109786-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014067-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-16 | — | — | WO | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | MEN1 3925/4885KMT2A 82/4885ACHE 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.